Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

NCT03691311 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasm Female
Stage I Breast Cancer
Stage II Breast Cancer
Hormone Receptor Negative Neoplasm
Hormone Receptor Positive Tumor

Interventions

DRUG: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Sponsor

Institut Català d'Oncologia

Collaborators

[object Object]